Peking University/Tsinghua University Angew: Recombinant protein-based supramolecular nanocarriers can improve the bioavailability of hydrophobic prodrugs to treat osteosarcoma

Supramolecular nanomedicine assembly based on supramolecular chemistry has developed into an effective drug treatment strategy. However, there are few studies on using engineered proteins as the building blocks of nano-formulations. Peking University Peoples Hospital Wei Guo, Tsinghua University Liu Kai researcher and Chao Ma developed a new type of recombinant protein-based nanomedicine carrier that can efficiently load and deliver the hydrophobic prodrug Aldoxorubicin.







Key points of this article:

(1) This strategy can achieve a significantly enhanced anti-tumor effect in the osteosarcoma (OS) model. Experimental results show that the half-life of this nano-drug has reached two days, and its corresponding bioavailability has also increased by 17 times, which is significantly better than other drugs and can be used to construct a long-acting therapeutic operating system.






(2) At the same time, the drug system also greatly reduces off-target side effects of prodrugs, including cardiotoxicity and lung metastasis. In summary, this assembly strategy can be used to design advanced nano-delivery systems to achieve more efficient cancer treatments.







references

Shidong Wang. et al. Improving Bioavailaibity of Hydrophobic Prodrugs through Supramolecular Nanocarriers based on Recombinant Proteins for Osteosarcoma Treatment. Angewandte Chemie International Edition. 2021

DOI: 10.1002/anie.202101938

https://onlinelibrary.wiley.com/doi/10.1002/anie.202101938